NTRZ.OB

[Se7en]

Looks a bit like a hammer today, Still following the 9MA ...

[Se7en]

Awesome volume today, back above the 9MA, MACD ticking up! Now let's get that 1.80 resistance out of the way! 

[setravis]

EL DORADO HILLS, Calif., Oct 23, 2006 /PRNewswire-FirstCall via COMTEX/ -- NutraCea, (NTRZ, Trade) the world leader in stabilized rice bran technology, announced today the addition of Joseph Gutman, M.D. to its Medical Advisory Board and as a strategic consultant.

Dr. Gutman currently resides in Phoenix, Arizona and manages a private practice specializing in internal medicine, endocrinology and metabolism. He is also the Chairman of the Department of Medicine at the Desert Samaritan Hospital in Mesa, Arizona. Other current positions include Director, Endothelial Pathology Laboratories Department of Biochemistry and Cell Biology at Arizona State University and Member of the Board of Directors of the European Arteriosclerosis Society. Dr. Gutman has authored over 330 medical publications to date and has 16 memberships to various medical associations including the American Society of Internal Medicine, American Diabetes Association, and the American Heart Association. Dr. Gutman has also served as a medical consultant on various healthcare issues, including consulting for several professional sports teams.

"I am delighted to welcome a very experienced and highly talented medical doctor to NutraCea and we look forward with to working with him. I am confident that Dr. Gutman's extensive academic and clinical experience will add immeasurably to our research and development capabilities," said Brad Edson, CEO of NutraCea.

"I am pleased to see that NutraCea is diligently pursuing the commercialization of their stabilized rice bran fractions that may have numerous health benefits for the management of specific disease states, particularly the dysmetabolic syndrome, arteriosclerosis and diabetes, which I am keenly interested in. I look forward to offering my assistance in both the academic and clinical investigation to further research the potential medical and healing benefits of their medical foods," said Dr. Gutman.

"Dr. Gutman's role on the medical advisory board and as a strategic advisor will be to assist the Company in the areas of scientific research, clinical studies and product development. His expertise and background, especially in the areas of metabolism and coronary artery disease, will help us to scientifically validate the benefits of our products and develop health specific formulas using our stabilized rice bran fractions and intellectual property portfolio," stated Margie Adelman, Senior Vice President of NutraCea.

About NutraCea

NutraCea is the world leader in production and utilization of stabilized rice bran. NutraCea holds many patents for stabilized rice bran production technology and proprietary nutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the underfed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program.

Forward Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.


 
     Company Contact:                  Investor Relations Contact: 
     Margie Adelman                    Stephen D. Axelrod, CFA 
     Senior V.P. NutraCea              Wolfe Axelrod Weinberger Assoc, LLC 
     916-933-7000 Ext. 646             212-370-4500 
     916-220-3500 cell                 [email protected] 
     [email protected] 
                                       Media Relations Contact: 
                                       Alisa D. Steinberg 
                                       Wolfe Axelrod Weinberger Assoc, LLC 
                                       212-370-4500 
                                       [email protected] 

SOURCE NutraCea


Margie Adelman, Senior V.P. of NutraCea, +1-916-933-7000, ext. 646, +1-916-220-3500 
cell, or [email protected]; or Investor Relations: Stephen D. Axelrod, CFA, 
[email protected], or Media Relations: Alisa D. Steinberg, 
[email protected], both of Wolfe Axelrod Weinberger Assoc, LLC, +1-212-370-4500, 
for NutraCea 

http://www.nutracea.com 

Copyright (C) 2006 PR Newswire. All rights reserved ********************************************************************** As of Thursday, 10-19-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 07-05-2006 for NTRZ @ $1.07. For more information on Comtex SmarTrend? Alert, contact your market data provider or go to CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2006 Comtex News Network, Inc. All rights reserved.

[setravis]

Awesome volume today, back above the 9MA, MACD ticking up! Now let's get that 1.80 resistance out of the way! 

Let's bust that Resistance ! 
Back up there with some monster volume....

Recent CandleStick Analysis
Very Bullish
Oct-24-2006 Bullish Engulfing 

52wk Range: 0.60 - 1.75
Volume: 4,122,723
Avg Vol (3m): 635,572

Technicals
MACD is Bullish
Stochastic is Bearish.....but OverSold 
Record Price High
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
12.42%above 13-day MA
31.76%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $88.59 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2006
Last Analyst Rating: N/A

[Ramsburg]

Update:
A cool development here, NTRZ just visited its 2005's high of $1.81 during the session, volume was huge, and a long white candle is now pointing some upside intentions for this stock.
We already sold half of this position last week, so we don't have much risk here, and we are curious about this move. The chart by itself suggests short term upside continuation for this setup, lets wait.

Trading Plan:
HOLD

Regards,

[Michael]

A cool development here, NTRZ just visited its 2005's high of $1.81.

Cool indeed or should we say hot? Nutracea has broken through 1.81 and is trading at 52 weeks high.

The volume has surged in October and the stock could go much higher from here.

Try to read through the first post in this thread. The potential in this business model is huge and it seems that the company really has got things together to realise the potential.

Try also to read this press release: http://biz.yahoo.com/prnews/060925/sfm093.html?.v=63

This is old news but it is worth to read again. Because it gives confidence in the management and is also a good sign that future expansion will be in line with the budget.

This is penny stock by choice. I think they will finally decide to move to one of the major exchanges but right now they don't give a dime. They are too busy putting a great business together.

[Terliso]

Projected Target price around $2.00 bucks

I think my $2.00 target price is very conservative...
how about $3.00 bucks...

[setravis]

Brake of the resistance @ $1.81
3 year chart Symmetrical Triangle....BreakOut !

Recent CandleStick Analysis
Bullish
Oct-24-2006 Bullish Engulfing 

Support @ $1.74...1.65...1.58
Resistance @ $1.91

52wk Range: 0.60 - 1.81
Volume: 991,893
Avg Vol (3m): 712,765

Technicals
Record Price High

Last Price Quote is:
14.61%above 13-day MA
35.77%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $88.59 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2006
Last Analyst Rating: N/A

[Ramsburg]

Projected Target price around $2.00 bucks

I think my $2.00 target price is very conservative...
how about $3.00 bucks...

Hi Terliso I don't know about $3.00, but $2.00 looks conservative for sure  

A cool development here, NTRZ just visited its 2005's high of $1.81.

Cool indeed or should we say hot? Nutracea has broken through 1.81 and is trading at 52 weeks high.

The volume has surged in October and the stock could go much higher from here.

Try to read through the first post in this thread. The potential in this business model is huge and it seems that the company really has got things together to realise the potential.

Try also to read this press release: http://biz.yahoo.com/prnews/060925/sfm093.html?.v=63

This is old news but it is worth to read again. Because it gives confidence in the management and is also a good sign that future expansion will be in line with the budget.

This is penny stock by choice. I think they will finally decide to move to one of the major exchanges but right now they don't give a dime. They are too busy putting a great business together.

Hi M Lets just say Hot  And thanks for your update 

Trading Plan:
HOLD

[Se7en]

Can you say 2$!!! 

[setravis]

Strong indications of market ability of their rice bran products.
NutraCea has unlimited potential to become a ground-floor power in the rice bran-based nutraceuticals marketplace, with their patented bran stabilization technology, and their products and their supply chain initiatives. 2006 will tell what their long termfuture should be.



Record 2nd Quarter Results

Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued success of the sale of its nutraceutical through direct to consumer marketing during quarter ended December 31, 2005. Approximately 62% of revenues in the quarter were from infomercial sales and 38% from the Company's expanded product lines and increased demand of it value added ingredients for the functional food industry and animal markets.

Total revenues for the six months ended June 30, 2006 were $7,947,726, compared to total revenues of $758,545 for the six months ended June 30, 2005, an increase of over 948%. The significant improvement in improved revenues and financial performance on a quarterly comparative basis are a culmination of the merger with RiceX, direct marketing of its expanding proprietary patented product line and sales of its core products into the functional food industry and animal markets during the quarter ended December 31, 2005.

NutraCea reported net income of $399,434 or $0.01 per share for the second quarter of 2006 based on weighted average shares outstanding of 71,791,913, compared to a net loss of $(1,800,084), or $(0.05) per share in 2005 based on 36,793,254 weighted average shares outstanding.

NutraCea had a net income of $165,860 or $0.00 per share for the six months ended June 30, 2006 based on weighted average shares outstanding of 68,808,345, compared to a net loss of $(2,664,777), or $(0.07) per share in 2005 based on 36,355,262 weighted average shares outstanding.

NutraCea reported positive earnings before interest, taxes, depreciation and amortization (EBITDA)* of $684,559 in the second quarter of 2006 compared to a negative EBITDA of $1,540,175 in the second quarter of 2005, an improvement of $2,224,734. In addition, EBITDA* for the six month period was a positive $717,452 compared to a negative EBITDA of $2,153,530 in the first six months of 2005, an improvement of $2,870,982.

Brakeout of the Ascending Triangle (continuation) pattern.
Then Breakout of the Cup with Handle (continuation) pattern
New 52 wk High

52wk Range: 0.60 - 1.87
Volume: 2,362,066
Avg Vol (3m): 723,953

Technicals
Record Price High

Last Price Quote is:
21.93%above 13-day MA
45.41%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $88.59 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2006
Last Analyst Rating: N/A

[gmarc66]

Great work Setravis on catching this one on an early breakout ...enjoy ur green

Stock looks great. Do u have a target in mind? 

This also had a g-spot breakout by the way, at 1.74. i believe it was.

glta

julia

[Ramsburg]

Update:
After the recent breakout, it's normal to watch some consolidation here. The $1.80 level is now a support, so let's just wait for some consolidation here.

Trading Plan:
HOLD

Regards,

[Ramsburg]

Update:
NTRZ continues to consolidate the recent price achievements after all these breakouts, some volatility with volume decreasing a bit (which is normal during consolidations).
We're just holding half of our original position, so we can wait for positive developments with no stress.

Trading Plan:
HOLD

Regards,

[Se7en]

NutraCea Announces Conference Call to Report Third Quarter Financial Results
Monday November 6, 8:00 am ET


EL DORADO HILLS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ - News), a leader in the production and marketing of stabilized rice bran and its derivatives, announced today it will report its third quarter financial results on Wednesday, November 15, 2006, before the financial markets open. The announcement will be followed by a conference call at 11:30 AM EST with the investment community, featuring Brad Edson, Chief Executive Officer and President of NutraCea.


Interested parties may participate in the call by dialing (877) 407-8037; international callers dial (201) 689-8037. In addition, the conference call will be available via a webcast that can be accessed at: http://www.vcall.com/IC/CEPage.asp?ID=111209 and will be archived for 30 days.


http://biz.yahoo.com/prnews/061106/sfm054.html?.v=70